Lenvatinib124, an oral inhibitor of VEGFR, FGFR, PDGFR, RET, and c-Kit, has been approved as a first-line treatment for HCC, on the basis of an open-label, phase III, multicenter, non-inferiority trial. This evidence concerns the gene PDGFRB and hepatocellular carcinoma.